

AMENDMENTS TO THE CLAIMS

1. **(Previously Presented)** A replicon RNA, comprising a nucleotide sequence comprising a 5' untranslated region comprising the nucleotide sequence of SEQ ID NO: 1, a core protein coding sequence comprising the nucleotide sequence of SEQ ID NO: 2, an E1 protein coding sequence comprising the nucleotide sequence of SEQ ID NO: 3, an E2 protein coding sequence comprising the nucleotide sequence of SEQ ID NO: 4, an NS2 protein coding sequence comprising the nucleotide sequence of SEQ ID NO: 5, an NS3 protein coding sequence comprising the nucleotide sequence of SEQ ID NO: 6, an NS4A protein coding sequence comprising the nucleotide sequence of SEQ ID NO: 7, an NS4B protein coding sequence comprising the nucleotide sequence of SEQ ID NO: 8, an NS5A protein coding sequence comprising the nucleotide sequence of SEQ ID NO: 9, an NS5B protein coding sequence comprising the nucleotide sequence of SEQ ID NO: 10, and a 3' untranslated region of genomic RNA comprising the nucleotide sequence of SEQ ID NO: 11, at least one selectable marker gene and/or at least one reporter gene, and at least one IRES sequence.

2. **(Original)** The replicon RNA according to claim 1, wherein said nucleotide sequence comprises the 5' untranslated region, the at least one selectable marker gene and/or the at least one reporter gene, and the at least one IRES sequence, and the core protein coding sequence, the E1 protein coding sequence, the E2 protein coding sequence, the NS2 protein coding sequence, the NS3 protein coding sequence, the NS4A protein coding sequence, the NS4B protein coding sequence, the NS5A protein coding sequence, the NS5B protein coding sequence, and the 3'

untranslated region, in this order in the 5' to 3' direction.

3. **(Cancelled)**.

4. **(Cancelled)**.

5. **(Previously Presented)** A replicon RNA, comprising a 5' untranslated region, a core protein coding sequence, an E1 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3' untranslated region, at least one selectable marker gene and/or at least one reporter gene, and at least one IRES sequence, wherein said replicon comprises an RNA comprising the nucleotide sequence shown in SEQ ID NO: 13; which has autonomous replication ability and virus particle production ability.

6. **(Previously Presented)** A method for producing a cell which replicates a replicon RNA and produces a virus particle, comprising introducing the replicon RNA according to claim 1 or 5 into a cell.

7. **(Original)** The method according to claim 6, wherein the cell is a proliferative cell.

8. **(Previously Presented)** The method according to claim 6, wherein the cell is a eukaryotic cell.

9. **(Original)** The method according to claim 8, wherein the eukaryotic cell is a human liver-derived cell, a human uterine cervix-derived cell or a human fetal kidney-derived cell.

10. **(Original)** The method according to claim 8, wherein the eukaryotic cell is a Huh7 cell, a HepG2 cell, an IMY-N9 cell, a HeLa cell or a 293 cell.

11. **(Previously Presented)** A cell obtainable by the method according to claim 6, which replicates the replicon RNA and produces the virus particle.

12. **(Withdrawn)** A method for producing a hepatitis C virus particle, comprising culturing the cell according to claim 11 to allow the cell to produce the virus particle.

13. **(Withdrawn and Currently Amended)** An isolated hepatitis C virus particle obtainable by the method according to claim 12.

14. **(Withdrawn)** A method for producing a hepatitis C virus-infected cell, comprising culturing the cell according to claim 11 and infecting other cells with the virus particle in the culture.

15. **(Withdrawn and Currently Amended)** An isolated hepatitis C virus-infected cell obtainable by the method according to claim 14.

16. **(Withdrawn and Currently Amended)** A method for screening an anti-hepatitis C virus substance, comprising culturing, in the presence of a test substance, at least one selected from the group consisting of following (a), (b) and (c):

(a) the cell according to claim 11,

(b) an isolated cell infected with the hepatitis C virus infected cell particle produced by the cell of (a), and

(c) the hepatitis C virus particle and a hepatitis C virus permissive cell;

— and detecting the replicon RNA or the virus particles in the resulting culture.

17. **(Withdrawn and Currently Amended)** A hepatitis C ~~vaccine~~immunogenic composition, comprising the hepatitis C virus particle according to claim 13 ~~or a part thereof~~.

18. **(Withdrawn and Currently Amended)** A method for producing a hepatitis C ~~vaccine-immunogenic composition~~ by using the hepatitis C virus particle according to claim 13 ~~or a part thereof~~ as an antigen.

19. **(Withdrawn and Currently Amended)** A method for producing a hepatotropic virus vector for gene therapy by ~~using~~integrating an RNA encoding a foreign gene into the replicon RNA according to claim 1.

20. **(Withdrawn and Currently Amended)** A hepatotropic virus vector obtainable by the method according to ~~claim 18~~claim 19.

21. **(Withdrawn and Currently Amended)** A method for replicating and/or expressing a foreign gene in a cell, comprising inserting an RNA encoding the foreign gene to the replicon RNA according to claim 1 and introducing it into said cell and culturing said cell.

22. – 23. **(Cancelled)**

24. **(Withdrawn)** The method according to claim 21, wherein the cell is a proliferative cell.

25. - 27. **(Cancelled)**